Soligenix Advances Psoriasis Treatment in $67B Market Opportunity
November 6, 2025 — Soligenix advances SGX302 phase 2a trial for psoriasis treatment, building on promising data in the $67B dermatology market. Company expands hypericin therapy pipeline.